In brief
- Governor Jenniffer González-Colón signed Executive Order 2026-037 on August 4, establishing a clinical research pilot program for psychoactive substances in Puerto Rico.
- The program highlights three experimental substances: ibogaine, psilocybin, and MDMA.
- The Department of Health must build the regulatory infrastructure and coordinate with the Puerto Rico Veterans Advocate Office to explore veteran participation.
Puerto Rico Governor Jenniffer González-Colón signed an executive order on August 4 launching a clinical research pilot program focused on substances currently considered experimental: ibogaine, psilocybin, and MDMA. The measure does not legalize their use, but it paves the way for the island to build—in coordination with federal authorities and universities—the infrastructure necessary for rigorous clinical trials.
What Executive Order 2026-037 establishes
The document creates the “Emerging Therapies Clinical Research Pilot Program” and, within the Department of Health, a Scientific and Regulatory Advisory Committee tasked with designing the trial framework. That committee must submit progress reports and, subsequently, a final report with recommendations on how to move forward. The Department of Health itself is charged with building from scratch the scientific, regulatory, and operational infrastructure needed to conduct the trials on the island, collaborating with university networks, hospital systems, and federal partners.
Veterans and the broader context
One of the most concrete provisions in the order is the mandate to coordinate with the Puerto Rico Veterans Advocate Office to explore the participation of former military personnel in future trials—a group that has driven much of the political momentum behind these therapies across the United States. González-Colón framed the decision in public health terms: “scientific innovation represents an opportunity to transform the future of Puerto Rico’s healthcare system,” adding that with this order the island seeks “to move toward becoming a benchmark in clinical research.” The administration cited mental health conditions, neurodegenerative diseases, and substance use disorders as motivating factors. The order comes four months after President Trump signed a federal executive order in April to accelerate the review of psychedelic drugs, and it also leverages the island’s industrial footprint: a $50 billion pharmaceutical industry that manufactures around 90% of the world’s pacemakers.
What this means
A signed executive order in Puerto Rico does not mean that ibogaine, psilocybin, or MDMA can be administered outside of a trial tomorrow: all three substances remain classified by the DEA under Schedule I, and any therapeutic application ultimately depends on FDA approval for each indication. What shifts is the institutional readiness: a territory with major pharmaceutical manufacturing capacity and without the political friction of a mainland state is positioning itself as a clinical trial hub—a move that could accelerate data generation if it draws sponsors and capital. As with any executive order, its real-world impact will depend on whether the newly formed committee receives funding and whether local hospitals and universities step up with concrete projects. For those tracking policies on ibogaína and MDMA, this marks another piece in the evolving landscape of clinical research across the United States and its territories.
Source
- Marijuana Moment. Puerto Rico Governor Signs Psychedelics Executive Order. Marijuana Moment, August 5, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
